Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Please note: We are reviewing Western blot images included in the antibody testing data in our catalog, including those provided by third parties. Unless expressly labeled or annotated as “raw-unedited”, Western blot images included in the antibody testing data in our catalog may have been edited, optimized or otherwise adjusted for presentation.
MA5-15556 targets KDR in indirect ELISA, FACS, IF, and WB applications and shows reactivity with Human samples.
The MA5-15556 immunogen is purified recombinant extracellular fragment of human KDR (aa20-764) fused with hIgGFc tag expressed in HEK293 cells.
MA5-15556 detects KDR which has a predicted molecular weight of approximately 152kDa.
KDR (FLK1, VEGFR2) is a type III receptor tyrosine kinase. It binds vascular endothelial growth factor with high affinity in vitro, and is expressed early in development by endothelial cell precursors. FLK1 (VEGF Receptor 2) encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc. Mutations of FLK1 (VEGF Receptor 2) are implicated in infantile capillary hemangiomas.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
蛋白别名: CD309 antigen; sCD309; soluble CD309; soluble VEGFR 2; VEGF R2